Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2025-08-14 Interim / Quarterly Rep…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
QUARTERLY REPORT
Interim / Quarterly Report Q2 2025
2025-08-14 English
Option Agreement for the Repurchase of Warrants
Regulatory Filings Classification · 98% confidence The document explicitly states it is a "FORM 8-K" filed pursuant to the Securities Exchange Act of 1934. Form 8-K is used to report unscheduled material events or corporate changes that shareholders should know about. The content details an "Item 1.01 Entry into a Material Definitive Agreement" regarding an Option Agreement for the Repurchase of Warrants, and an "Item 8.01 Other Events" providing a clarification related to a previous Form 10-Q. Since Form 8-K is a current report of material events and does not fit the definitions for Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or Proxy Statement (DEF 14A/PSI), the most appropriate classification for a general current report filing that details material agreements and corporate actions is the general Regulatory Filings category (RNS), as it is a standard SEC filing type not covered by the more specific options provided. However, given the structure and purpose of Form 8-K as a 'Current Report' detailing specific material events (like material definitive agreements), it often falls under a general regulatory filing category. Since RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' and Form 8-K is a primary regulatory filing, RNS is the best fit among the provided options for a non-periodic, material event disclosure.
2025-07-23 English
Option Agreement for the Repurchase of Warrants
Report Publication Announcement Classification · 98% confidence The document is a filing notification from Oramed Pharmaceuticals Inc., reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The key indicator is the line: "Attached hereto is a report on *Form 8-K*" followed by a PDF filename. A Form 8-K is an 'Other Report or Announcement' filed with the SEC, typically used for material, unscheduled events. Since this document is a short notification announcing the attachment of a specific SEC form (8-K), and it does not contain the full content of the 8-K itself, it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing the publication of a report (Form 8-K), RPA is more precise than the general RNS fallback. The document length is very short (1834 chars), supporting the RPA classification based on the 'MENU VS MEAL' rule.
2025-07-23 English
CURRENT REPORT
Regulatory Filings
2025-07-23 English
Other Report or Announcement
Proxy Solicitation & Information Statement Classification · 100% confidence The document explicitly states it is a "SCHEDULE 14A" and a "Definitive Proxy Statement" filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It contains a "NOTICE OF ANNUAL MEETING OF STOCKHOLDERS" and details the proposals to be voted on at that meeting (election of directors, ratification of auditors, amendment to stock plan). This content perfectly matches the definition of a Proxy Statement, which corresponds to the filing type code DEF 14A (Proxy Solicitation & Information Statement). Although the definition for DEF 14A is listed as Remuneration Information, the document structure and explicit header 'SCHEDULE 14A' and 'Definitive Proxy Statement' strongly indicate the intent is to classify this as the primary proxy document, which aligns best with the provided option 'DEF 14A'.
2025-07-18 English
Other Report or Announcement
Report Publication Announcement Classification · 95% confidence The document explicitly states it is an 'Other Report or Announcement' filed under Israeli regulations for a foreign corporation. Crucially, it states: 'Attached hereto is a report on *Proxy Statement* *Oramed_DEF14_20250718_isa.pdf*'. A Proxy Statement is the primary document used to solicit shareholder votes, which corresponds to the definition of Proxy Solicitation & Information Statement (PSI). However, the document itself is a short announcement (1844 chars) stating that the Proxy Statement is attached, fitting the 'MENU VS MEAL' rule for a Report Publication Announcement (RPA). Furthermore, the term 'DEF 14A' is mentioned in the filename, which relates to executive compensation (DEF 14A code), but the primary content description points to a Proxy Statement (PSI). Given the structure of announcing an attached Proxy Statement, RPA is the most accurate classification for this specific filing wrapper, as it is announcing the publication of the main document.
2025-07-18 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.